Screener
Ultragenyx Pharmaceutical RARE Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Common stock, par value of $0.001 per share—250.0 shares authorized; outstanding—98.6 in 2026 and 96.6 in 2025 | — | — |
| Treasury stock, at cost, 0.3 shares in 2026 and 0.2 shares in 2025 | (10) | (8) |
| Deferred compensation obligation | 10 | 8 |
| Additional paid-in capital | 4,518 | 4,451 |
| Accumulated other comprehensive income | — | 1 |
| Accumulated deficit | (4,809) | (4,532) |
| Total stockholders’ deficit | (291) | (80) |
| Total liabilities, noncontrolling interest and stockholders’ deficit | $1,264 | $1,532 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's total liabilities & equity?
- Ultragenyx Pharmaceutical (RARE) reported total liabilities & equity of $1.26B in Q2 2026.
- How has Ultragenyx Pharmaceutical's total liabilities & equity changed year-over-year?
- Ultragenyx Pharmaceutical's total liabilities & equity decreased by 3.2% year-over-year, from $1.31B to $1.26B.
- What is the long-term trend for Ultragenyx Pharmaceutical's total liabilities & equity?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total liabilities & equity has grown at a -2.7% compound annual growth rate (CAGR), from $1.76B to $1.53B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Ultragenyx Pharmaceutical's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude